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Abstract
Background: Major depressive disorder (MDD) is projected to rank second on a list of 15 major diseases in terms
of burden in 2030. The contribution of MDD to disability and health care costs is largely due to its highly recurrent
nature. Therefore, part of the efforts to reduce the disabling effects of depression should focus on preventing
recurrence, especially in patients at high risk of recurrence. The best established effective psychological intervention
is cognitive therapy, with indications for prophylactic effects after remission.
Methods/Design: In this randomized controlled trial (cost-) effectiveness of Preventive Cognitive Therapy (PCT)
after response to Acute Cognitive Therapy (A-CT) will be evaluated in comparison with Treatment As Usual (TAU).
Remitted patients that responded to A-CT treatment with at least two previous depressive episodes will be
recruited. Randomization will be stratified for number of previous episodes. Follow-ups are at 3, 6, 12 and 15 months.
The primary outcome measure will be the time to relapse or recurrence of depression meeting DSM-IV criteria for a
major depressive episode on the Structured Clinical Interview for DSM-VI Axis I Disorders (SCID-I). Costs will be
measured from a societal perspective.
Discussion: This study is the first to examine the addition of PCT to TAU, compared to TAU alone in patients that
recovered from depressive disorder with A-CT. Alongside this effect study a cost effectiveness analysis will be
conducted. Furthermore, the study explores potential moderators to examine what works for whom.
Trial registration: Netherlands Trial Register (NTR): 2599, date of registration: 11-11-2010.
Keywords: Depression, Relapse, Recurrence, Cognitive Therapy, Prevention
Background
High prevalence, and frequent relapse and recurrence
contribute to the public health significance of Major
Depressive Disorders (MDD). Depression is the most dis-
abling disorder worldwide measured in years lived with
disability [1]. In various recent epidemiological studies,
the annual prevalence in the general population varies
from 4 % to 6 % [2, 3]. Epidemiological estimates place
the lifetime prevalence of MDD at more than 16 % [4].
However, the major contribution of MDD to disability
and health care costs is largely due to its highly recurrent
nature. The large majority of individuals with MDD ex-
perience more than one episode and the probability of an-
other episode increases with each relapse or recurrence [5,
6]. Reported relapse and recurrence rates for high risk
groups, rise up to 60–70 % recurrence over 2 year [7, 8].
Apart from the number of previous episodes, residual
symptoms after remission are risk factors for recurrence
[9, 10]. Optimizing long-term outcomes is therefore an
important goal in the treatment of MDD, especially for
well-known high risk groups, i.e. patients with multiple
previous episodes and/or residual symptoms.
We know that acute phase treatment of depression
with Cognitive Therapy (A-CT) has a prophylactic effect
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[11]. After completing A-CT, patients are less likely to
relapse than after stopping a similar course of pharma-
cotherapy [12]. However, recent meta-analysis showed
that after remission on A-CT, many responders still have
a relapse-recurrence (29 % within 1 year and 54 % within
2 years) [8]. Other studies also show that after remission
a sizable number (40 %) will experience a return of
symptoms after treatment [9, 13].
The most commonly used treatment to prevent re-
lapses and recurrences is antidepressant medication
(AD). However, 70–80 % of patients are not willing to take
AD for a long period of time [14, 15]. Also non-adherence
is common among AD-users, which is troubling as pa-
tients’ protection from recurrence ceases on discontinu-
ation of AD and therefore increases the risk of recurrence
[16, 17]. Most patients prefer psychological interventions
to drug treatment, this is especially relevant in long term
treatment as studies show that patients’ treatment prefer-
ence is associated to compliance [18].
Jarrett and colleagues developed and tested a model of
Continuation-phase Cognitive Therapy (C-CT). C-CT
consists of ten sessions over a period of eight months and
is provided after 20 sessions of A-CT, both provided by the
same therapist. They found that C-CT reduces time to
relapse and recurrence compared with an assessment-
only control [19]. Responders to A-CT who received
C-CT were significantly less likely to relapse (10 %) com-
pared to those who received the assessment-only control
(31 %). In the same study responders to A-CT with un-
stable remissions also benefited (37 % vs 62 %). Further-
more, responders to A-CT with more residual symptoms
were more likely to require C-CT to avoid relapse than re-
sponders with lower or no residual symptoms [20]. Al-
though these results are promising they are not replicated
yet. Given the limited therapy resources, and the fact that
remitted patients might not be motivated to an interven-
tion that consists of eight months after remission, C-CT with
fewer sessions given within a two month time-period
would be desirable.
Building on this knowledge Bockting developed Prevent-
ive Cognitive Therapy (PCT). PCT is a form of Cognitive
Therapy aimed at treating an underlying vulnerability and
thereby inducing long-term effects on depression recur-
rence. After remission, sequential PCT is proven effective
in preventing relapse and recurrences in patients with
multiple episodes over 5.5–10 years compared to treat-
ment as usual (TAU) [7, 21, 22]. However, this study did
not include patients treated with A-CT. Therefore, the
(cost-) effectiveness of PCT after remission on A-CT is
still unknown and the main goal of this study. PCT differs
from C-CTas it is a brief intervention, only taking 8 weeks,
and can be given by another therapist than the one provid-
ing A-CT. Because PCT is shorter and given within two
months this might enhance possibilities for dissemination.
This study is the first to assess the (cost-) effectiveness
of 8 sessions of PCT in comparison with TAU in high risk
patients who remitted after receiving A-CT. A clinically
relevant difference between PCT and TAU might result in
enormous health effects on the population level.
Trial objectives
In this study, the addition of PCT to TAU will be com-
pared to TAU alone in patients that recovered from re-
current depressive disorder after treatment with A-CT.
Alongside this effectiveness study a cost-effectiveness
study will be done. It is hypothesized that adding PCT
to TAU is clinically superior tot TAU alone in prevent-
ing relapse and recurrence of depressive disorder.
Furthermore, the study explores potential moderators
to examine what works for whom. Potential mediators
will also be examined to explore the working mechanism
of PCT by assessing coping, social support, dysfunc-
tional attitudes, affiliation, daily stress and functioning,
and their association to risk of relapse in depression,
before, during and after treatment.
Methods/Design
Design
In this multi-center randomized controlled trial with a
follow-up of 15 months, we compare the addition of
PCT to TAU in patients who recovered from depressive
disorder after receiving CT, to TAU alone. An economic
evaluation from a societal perspective will be performed
alongside this RCT.
The target population consists of patients with a his-
tory of two or more depressions which is a group at ele-
vated risk of relapse and recurrence of depression. This
group consumes a considerable amount of healthcare
mainly due to relapse rates witch rise which increasing
numbers of previous episodes as identified in several
studies [10].
Randomization at patient level will be undertaken by
an independent researcher using a computer-generated
random schedule and will be stratified by number of
previous depressive episodes. The randomization is ac-
cessible solely by the independent researcher. For a Flow
diagram of the assessment methods see Fig. 1.
The interventions
Acute Cognitive Therapy
All patients who enter this study have received Acute
Cognitive Therapy (A-CT) during the acute phase of de-
pression consisting of at least 8 sessions specifically de-
signed for patients with depression. A-CT is directed at
the identification of maladaptive cognitions. Each session
follows a fixed structure, with agenda setting, review of
homework, explanation of rationale of each session, and
assignment of homework [23].
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Fig. 1 Flow-chart of the study
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Treatment as usual
TAU consists of usual care that patients receive in pri-
mary care and in secondary care, after A-CT for depres-
sion. TAU may include no treatment at all or anti-
depressant maintenance medication, which is in most
cases provided by the general practitioner (GP). Thus,
use of AD will not be an exclusion criterion. Treatment
received as part of TAU will be included as covariate in
the final analysis. A comparison of the intervention with
TAU is relevant from a public health perspective since it
would help to demonstrate the intervention’s added
value over and above TAU. We will not intervene with
TAU, but closely monitor healthcare utilization in TAU.
Preventive Cognitive Therapy
After response to A-CT, there will be a minimum two
month waiting period before PCT will start. PCT con-
sists of eight individual sessions once a week, offered as
sequential treatment after response to A-CT. PCT is an
adapted type of CT specifically developed to prevent re-
lapse in recurrent depression. Similar to regular CT,
each PCT session follows a fixed structure, with agenda
setting, review of homework, explanation of rationale of
each session, and assignment of homework [24].
PCT differs from A-CT in several aspects. Unlike A-CT,
PCT is not primarily directed toward modifying negative
thoughts. Instead, it starts with the identification of nega-
tive thoughts and dysfunctional attitudes and beliefs, aided
by a self-report questionnaire with examples of attitudes
and specific techniques such as the downward arrow tech-
nique. The focus of treatment is then directed on examin-
ing these attitudes using different cognitive techniques
such as Socratic questioning and identification of positive
phantasy attitudes. Moreover, patients are encouraged
to practice with alternative attitudes in the final ses-
sions. In addition, unlike with traditional A-CT, specific
attention will be paid to enhancing the memory and re-
trieval of positive experiences and making a personal
prevention plan [21]. A specific manual for the client
and therapist has been published describing the struc-
ture of the treatment [24].
Therapists
Therapists in the PCT condition are trained psycholo-
gists who are specialized in CBT. They will receive a one
day training in PCT from the author of the PCT proto-
col that is used in this study [24]. During the study the
therapists participate in regular supervision groups led
by the trainer, as well as peer supervision groups led by
the principal investigator. Regular supervision will be
held once a week, the peer supervision once every
four months. The therapists who perform the PCT are
not the same therapists that provided the A-CT.
Sample size
In total, 214 patients will be recruited. This sample size is
needed to detect a difference in the primary outcome (cu-
mulative proportion of relapse/recurrence rates over
15 months) of at least 20 % between the conditions in a 1-
sided test at alpha = 0.05 and a power of (1-beta) = 0.80.
For this we need 85 participants in each condition. Allow-
ing for a drop out of 20 % over the two years, we need to
include 107 participants in each condition at baseline.
Referral and recruitment
The first recruitment strategy is via secondary mental
healthcare facilities. Patients who are currently treated
for depression with cognitive therapy will be informed
by their therapist about this study. Patients will also be
offered written information by either a research associate
or via e-mail or post. Secondly, patients who have been
treated for depression with A-CT in the past will be in-
formed through their former mental healthcare facility.
They will receive written information about the study
and a request to sign the informed consent. The third
recruitment strategy is via media. The study will be pro-
moted through press releases to local media, advertise-
ments and digital online promotions using the study’s
website. If someone is interested in participating, s/he
can contact the researcher by e-mail, phone or through
the website.
Informed consent
We inform patients about the study before they sign in-
formed consent. They will receive a letter containing all
the information and a digital informed consent. If they
agree to enter the trial, they fill out the digital informed
consent and then are contacted by a researcher for the
baseline assessment.
Approval of the Stichting Medisch-Ethische Toetsings-
commissie Instellingen Geestelijke Gezondheidszorg
(METiGG) is obtained and the trial is conducted in
compliance with the Declaration of Helsinki [25].
Inclusion criteria
We will include patients:
– with at least two previous depressive episodes
– who are currently in remission according to DSM-IV
criteria, for at least two months as assessed by the
Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I)
– with none to mild depressive symptoms defined as a
current score of <14 in the 17 item Hamilton
Depression rating scale
– who have received A-CT, with a minimum of eight
sessions
– who are fluent in Dutch
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Exclusion criteria
We exclude patients who have:
– current mania or hypomania or a history of bipolar
illness, any psychotic disorder (current and
previous)
– current alcohol or drugs misuse
– acute predominant anxiety disorder
There are no restrictions with respect to co-morbidity
on Axis II and III, in exception of a concurrent chronic
somatic illness that is as risk factor for relapse and
recurrence.
Withdrawal
Participants can withdraw from treatment or from the
study at any time. If they decide to withdraw from the
trial treatment we ask them whether they are willing to
finish the remaining assessments.
Assessment of eligibility and baseline measures
After filling in the informed consent participants are
contacted by a researcher for baseline assessment. This
assessment is done at the secondary care facility, by
phone or at the participant’s home, depending on their
preference. The researcher will check for potential inclu-
sion and exclusion criteria through an initial screening.
They will start the baseline assessment using the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) [26] and Hamilton Depression rating scale
(HAM-D) [27]. Afterwards the researcher contacts the
primary investigator to evaluate the participant and de-
cide whether the participant can participate in the study.
If the participant cannot participate in the study, s/he
will be contacted by the researcher. If the participant is
eligible to participate in the study, s/he will be contacted
by the primary investigator to receive the allocation.
They will also receive the self-report measures complet-
ing the baseline measure by e-mail. After 3 months, all
participants received a one year magazine subscription.
For a complete overview of the procedure see Fig. 1.
Outcome measures/Instruments
Every participant will be monitored over a period of
15 months. After baseline assessment, follow up assess-
ments of patients in the TAU condition will be per-
formed at 1, 2, 3, 6, 12 and 15 months. Patients in the
experimental condition will be assessed every session
and after 3, 6, 12, and 15 months. The assessments done
at baseline and at 15 months consist of an interview and
self-report measures. Al interviews will be performed by
trained assessors. The assessors are blind to the alloca-
tion of the participants. The remaining assessments are
self-report questionnaires, which are filled in by the
patients and their therapists. For an overview of the as-
sessments at baseline, post treatment and follow up see
Table 1. For an overview of the assessments after each
session see Table 2.
Primary outcome
The primary outcome measure will be the cumulative
proportion of relapse or recurrence of depression meet-
ing DSM-IV criteria for a major depressive episode ac-
cording to the Structured Clinical Interview for DSM-VI
Axis I Disorders (SCID-I) over a follow-up period of
15 months.
Secondary outcome
Secondary outcome variables are;
– Depressive symptom severity as measured with the
HAM-D [27], Inventory of Depression Symptomatology
(IDS) [28] and the Beck Depression Inventory
(BDI-II) [29].
– Duration of relapse/recurrence.
– Number of relapses.
– Quality of life as measured by the EuroQol (EQ-5D).
The EQ-5D scores will be used to calculate utilities
using the Dutch tariff [30]. Quality-adjusted life-years
(QALYs) will be calculated by multiplying the utility
of a health state by the time spent in this health state
using linear interpolation between time points. Higher
QALY scores indicate higher quality of life.
– Health care utilization and productivity losses will
be measured with an adapted version of the Trimbos
Questionnaire for Costs associated with Psychiatric
illness (TIC-P), a widely used health service receipt
interview in economic evaluations [31]. Costs that
will be included in the economic evaluation are
direct medical and non-medical costs, and indirect
costs. Resource utilization (GP visits, hospital days,
ect.) will be valued using Dutch standard costs [32].
Using the TiC-P, both absenteeism and presenteeism
(working less efficiently while at work) will be
measured. Productivity losses will be valued using
the friction cost method.
– The frequency and intensity of daily stress as
measured with the Brugha and the Everyday
Problem Checklist (EPCL) [33].
Other parameters
As potential moderators, mediators and mechanisms of
change we will analyze; personality traits measured by
the Personality Diagnostic Questionnaire (PDQ-4) [34],
psychological mindedness measured by the Psychological
Mindedness Scale (PMS) [35], mastery measured by the
Mastery scale [36], social support measured by the
Sociale Steun Lijst (SSL-I) [37], coping measured by the
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Utrechtse Coping Lijst (UCL) [38], experiential accept-
ance and avoidance measured by the Acceptance and
Action Questionnaire (AAQ-II) [39], functioning mea-
sured by the Outcome Rating Scale (ORS) [40], affili-
ation measured by the Affiliation scale [41], emotions
measured by the Positive and Negative Affect Schedule
(PANAS-X) [42], dysfunctional attitudes measured by
the Dysfunctional Attitude Scale (DAS) [43, 44], social
en interpersonal functioning measured by the Inventory
of Personal Problems (IIP-C) [45], depressive mood
Table 1 Overview of assessments
Measure Description T0 T1 T2 T3 T4 T5 T6a
Interviews
SCID-I DSM-IV-TR Axis I disorders x x
HAM-D Depressive symptoms and severity x x
Self report measures
IDS-SR Depressive symptoms x x x x x
IIP-C Social and interpersonal functioning x
EQ-5D Quality of life x x x x x
TIC P Direct/indirect costs x x x x x
PMS Psychological mindedness x x
PDQ-4 Personality x
Brugha Life events x x
EPCL Everyday problems x x x
Mastery scale Mastery x x x x x
VAMS Mood x x x x x
IVM Victimization x
SSL-I Social support x x x x x
UCL Coping x x x x x
AAQ Experiential acceptance and avoidance x x x
ORS Functioning x x x
Affiliation Affiliation x x x
PANAS-X Emotions x x x
DAS Dysfunctional attitudes x x x x
BDI Depressive symptoms x x x
aT0 = Baseline, T1 = 1 month, T2 = 2 months, T3 = 3 months, T4 = 6 months, T5 = 12 months, T6 = 15 months
Table 2 Overview of assessments after each session
Measure Description S1 S2 S3 S4 S5 S6 S7 S8a
UCL Coping x x x x
SSL-I Social support x x
AAQ Experiential acceptance and avoidance x x
ORS Functioning x x x x x x x x
SRS Session evaluation x x x x
BDI Depressive symptoms x x x x x x
WAI-SR Therapeutic relationship x x x x
DAS-17 Dysfunctional attitudes x x x x x x x x
Affiliation Affiliation x x x
Daily h. Daily stressors x x x x
PANAS Emotions x x x x x x x x
aS = session number
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measured by a one item mood scale [46], session evalu-
ation measured by the Session Rating Scale (SRS) [47],
therapeutic relationship measured by the Working Alli-
ance Inventory-Short Revised (WAI-SR) [48], mood mea-
sured by a one-item Visual Analogue Mood Scale (VAMS)
[46] and Victimisation measured by the Dutch version of
the Integral Safety/Security Monitor (IVM) [49].
Analysis
The primary outcome measure will be the time to re-
lapse or recurrence meeting DSM-IV criteria for a major
depressive episode on the Structured Clinical Interview
for DSM-VI (SCID-I). Occurrence of relapse or recur-
rence (current or since the last assessment point) will be
assessed after 15 months, by trained psychologists who
are blind to the treatment condition. Cox regression
analysis will be performed. Analysis will be conducted
by intention to treat, including all subjects randomized
in the study, and per protocol. Statistical significance will
be set at p < .05. The time (in weeks) of relapse or recur-
rence to Major Depression, as defined above, will be the
dependent variable in survival analysis. The treatment
group will be used as predictor, and the stratification
variable will be used as covariate. In addition, time since
previous episode and time since last treatment will be
included as covariates.
In addition, we use the HAM-D, to assess the severity
of depression at both time points, together with the
SCID-I.
Mixed-model analysis will be used for the quantitative
measures. As covariates we will use the stratification
variable (number of episodes). Potential moderators to
be examined include gender, residual symptoms of de-
pression, duration of remission, duration of last episode,
coping, age of onset and current use of AD.
For the economic evaluation the relationship between
costs and health outcomes of the two treatment condi-
tions will be evaluated using a societal perspective. Both
a cost-effectiveness analysis with depression-free survival
time as effect measure and a cost-utility analysis with
QALYs as effect measure will be performed.
The economic evaluation will be done according to
the intention-to-treat principle. Incremental cost-
effectiveness ratios (ICERs) will be calculated by dividing
the difference in mean total costs between the treatment
groups by the difference in mean effects between the
treatment groups. Bootstrapping with 5000 replications
will be used to estimate 95 % confidence intervals
around cost differences and the uncertainty surrounding
the ICERs. Rubin’s rules will be used to pool the results
from the different multiply imputed datasets. Uncer-
tainty surrounding the ICERs will be graphically pre-
sented on cost-effectiveness planes. Cost-effectiveness
acceptability curves showing the probability that the
intervention is cost-effective in comparison with usual
care for a range of different ceiling ratios will also be
estimated [50].
Discussion
High prevalence and frequent relapse and recurrence
contribute to the public health significance of MDD.
MDD is considered the most disabling disorder world-
wide measured in years lived with disability [1]. This
trial will be the first to compare short term individual
PCT to TAU following A-CT in patients with major de-
pression. Apart from the evaluation of the effectiveness
and cost-effectiveness, we examine what works for
whom, by measuring potential mediators and modera-
tors after each PCT session and throughout the entire
study.
Recent studies show that although long-term continu-
ation of AD is likely to be effective in preventing relapse
and recurrence, patients prefer psychological therapies
above taking ADs [14, 51]. Therefore, sequential PCT
following remission on A-CT may be a good alternative
or addition to TAU. Considering the substantial negative
effects on quality of life and the increased societal costs
associated with depression there is a need for short-term
and cost-effective interventions that can be provided by
any psychologist. The results of this study might im-
prove better treatment matching by examining media-
tors and moderators and thereby clarifying what is best
for whom. In addition, mediation variables will be exam-
ined to get more insight into the essential ingredients of
the preventive CT used. This trial aims to contribute to
the improvement of more efficient therapeutic interven-
tions to prevent relapse and recurrence in depression.
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